MyPeptideMatchCagrilintide is a long-acting amylin analogue in Phase 3 development, studied in combination with semaglutide (CagriSema). The CagriSema combination achieved approximately 22.7% body weight reduction at 68 weeks in the SCALE trial.
Amylin Analogue
Cagrilintide is a long-acting amylin analogue in Phase 3 development, studied in combination with semaglutide (CagriSema). The CagriSema combination achieved approximately 22.7% body weight reduction at 68 weeks in the SCALE trial.
Research Use Only — not intended for human consumption
Research peptides are sold for laboratory use only and are not intended for human consumption.
Week-by-week dosing, reconstitution steps, supplies checklist, and cycle tips.
No clinics in our directory yet. Browse all clinics.
Find a Peptide Clinic Near YouMyPeptideMatch.com does not provide medical advice. Always consult a qualified healthcare provider before starting any peptide therapy. Regulatory status may change.